FibroBiologics Announces $25 Million Financing
December 23, 2024 07:55 ET
|
Fibrobiologics, Inc.
HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
November 19, 2024 09:15 ET
|
Fibrobiologics, Inc.
HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of...
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
November 14, 2024 09:15 ET
|
Fibrobiologics, Inc.
HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 12, 2024 16:20 ET
|
Fibrobiologics, Inc.
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the...
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
October 29, 2024 09:15 ET
|
Fibrobiologics, Inc.
HOUSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
October 28, 2024 09:31 ET
|
Fibrobiologics, Inc.
HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
October 18, 2024 08:30 ET
|
Fibrobiologics, Inc.
HOUSTON, Oct. 18, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”) and Charles River Laboratories (“Charles River”), a leading global drug discovery, development,...
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
October 16, 2024 09:15 ET
|
Fibrobiologics, Inc.
HOUSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
October 11, 2024 09:31 ET
|
Fibrobiologics, Inc.
HOUSTON, Oct. 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa
September 30, 2024 09:31 ET
|
Fibrobiologics, Inc.
HOUSTON, Sept. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...